These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 17910803)

  • 1. Patient baseline characteristics in an open-label multinational study of betahistine in recurrent peripheral vestibular vertigo: the OSVaLD study.
    Pérez-Garrigues H; Kuessner D; Benecke H
    Curr Med Res Opin; 2007 Nov; 23(11):2753-61. PubMed ID: 17910803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of Betahistine by Patient-Reported Outcomes and its Tolerability Profile in Indian Patients with Vestibular Vertigo.
    Kirtane MV; Biswas A
    J Assoc Physicians India; 2017 Apr; 65(4):18-24. PubMed ID: 28527159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of betahistine on patient-reported outcomes in routine practice in patients with vestibular vertigo and appraisal of tolerability: experience in the OSVaLD study.
    Benecke H; Pérez-Garrigues H; Bin Sidek D; Uloziene I; D K; Sondag E; Theeuwes A;
    Int Tinnitus J; 2010; 16(1):14-24. PubMed ID: 21609908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Betahistine plus piracetam dual therapy versus betahistine monotherapy for peripheral vestibular vertigo: a confounder-corrected subanalysis of the OSVaLD study.
    Melnikov OA; Lilenko SV; Nauta J; Ouwens MJ
    Curr Med Res Opin; 2015 Nov; 31(11):1951-62. PubMed ID: 26121560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects and safety profile of betahistine in patients in the Russian contingent of OSVaLD, an open-label observational study in vestibular vertigo.
    Morozova SV; Alekseeva NS; Lilenko SV; Matsnev EI; Melnikov OA
    Int J Gen Med; 2015; 8():47-53. PubMed ID: 25653552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects and tolerability of betahistine in patients with vestibular vertigo: results from the Romanian contingent of the OSVaLD study.
    Băjenaru O; Roceanu AM; Albu S; Zainea V; Pascu A; Georgescu MG; Cozma S; Mărceanu L; Mureşanu DF
    Int J Gen Med; 2014; 7():531-8. PubMed ID: 25506241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of vestibular rehabilitation, with or without betahistine, on managing residual dizziness after successful repositioning manoeuvres in patients with benign paroxysmal positional vertigo: a protocol for a randomised controlled trial.
    Wu P; Cao W; Hu Y; Li H
    BMJ Open; 2019 Jun; 9(6):e026711. PubMed ID: 31217316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Double-blind, randomized, multicenter study comparing the effect of betahistine and flunarizine on the dizziness handicap in patients with recurrent vestibular vertigo.
    Albera R; Ciuffolotti R; Di Cicco M; De Benedittis G; Grazioli I; Melzi G; Mira E; Pallestrini E; Passali D; Serra A; Vicini C
    Acta Otolaryngol; 2003 Jun; 123(5):588-93. PubMed ID: 12875580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A study of the efficacy and safety of a new modified-release betahistine formulation in the treatment of vestibular vertigo and Meniere's disease].
    Parfenov VA; Zamergrad MV; Kazei DV; Nauta J
    Zh Nevrol Psikhiatr Im S S Korsakova; 2020; 120(12):42-48. PubMed ID: 33459540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Impact of Betahistine versus Dimenhydrinate in the Resolution of Residual Dizziness in Patients with Benign Paroxysmal Positional Vertigo: A Randomized Clinical Trial.
    Jalali MM; Gerami H; Saberi A; Razaghi S
    Ann Otol Rhinol Laryngol; 2020 May; 129(5):434-440. PubMed ID: 31810393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of medical therapy in the prevention of residual dizziness after successful repositioning maneuvers for Benign Paroxysmal Positional Vertigo (BPPV).
    Acar B; Karasen RM; Buran Y
    B-ENT; 2015; 11(2):117-21. PubMed ID: 26563011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of betahistine (48 mg/day) in patients with vestibular vertigo during routine practice: The VIRTUOSO study.
    Parfenov VA; Golyk VA; Matsnev EI; Morozova SV; Melnikov OA; Antonenko LM; Sigaleva EE; Situkho MI; Asaulenko OI; Popovych VI; Zamergrad MV
    PLoS One; 2017; 12(3):e0174114. PubMed ID: 28358888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meta-analysis of clinical studies with betahistine in Ménière's disease and vestibular vertigo.
    Nauta JJ
    Eur Arch Otorhinolaryngol; 2014 May; 271(5):887-97. PubMed ID: 23778722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Betahistine add-on therapy for treatment of subjects with posterior benign paroxysmal positional vertigo: a randomized controlled trial.
    Sayin I; Koç RH; Temirbekov D; Gunes S; Cirak M; Yazici ZM
    Braz J Otorhinolaryngol; 2022; 88(3):421-426. PubMed ID: 32978116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of high-dose betahistine on intractable dizziness in patients with uncompensated unilateral vestibulopathy.
    Takeda N; Sato G; Matsuda K; Ito J; Omori K; Ito Y; Kitahara T; Koizuka I; Shojaku H; Suzuki M; Doi K; Murofushi T; Yamashita H
    Auris Nasus Larynx; 2024 Apr; 51(2):401-405. PubMed ID: 37666746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of Benign Paroxysmal Positional Vertigo: A Comparative Study between Epleys Manouvre and Betahistine.
    Kaur J; Shamanna K
    Int Tinnitus J; 2017 Jun; 21(1):30-34. PubMed ID: 28723599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of betahistine in the treatment of peripheral vertigo.
    Ramos Alcocer R; Ledezma Rodríguez JG; Navas Romero A; Cardenas Nuñez JL; Rodríguez Montoya V; Deschamps JJ; Liviac Ticse JA
    Acta Otolaryngol; 2015; 135(12):1205-11. PubMed ID: 26245698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Trimetazidine versus betahistine in vestibular vertigo. A double blind study].
    Kluyskens P; Lambert P; D'Hooge D
    Ann Otolaryngol Chir Cervicofac; 1990; 107 Suppl 1():11-9. PubMed ID: 2240994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of betahistine treatment on dizziness and anxiety symptoms of BPPV patients.
    Erdur ZB; Evran N
    Niger J Clin Pract; 2023 Sep; 26(9):1383-1387. PubMed ID: 37794554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of a Fixed Combination of Cinnarizine 20 mg and Dimenhydrinate 40 mg vs Betahistine Dihydrochloride 16 mg in Patients with Peripheral Vestibular Vertigo: A Prospective, Multinational, Multicenter, Double-Blind, Randomized, Non-inferiority Clinical Trial.
    Scholtz AW; Hahn A; Stefflova B; Medzhidieva D; Ryazantsev SV; Paschinin A; Kunelskaya N; Schumacher K; Weisshaar G
    Clin Drug Investig; 2019 Nov; 39(11):1045-1056. PubMed ID: 31571128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.